injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk ... or $55 for five pen cartridges, adding that ...

In this other section I will discuss another key component of Novo Nordisk and Eli Lilly's revenues, namely the insulin market. Typically when we invest in a pharmaceutical company, the first ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs ...

The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a ...

Clarivate’s Drugs to Watch in 2025 report (PDF) predicts that Novo’s new once-weekly insulin Awiqli will pick ... Novo and Eli Lilly have been duking it out in the fields of diabetes and ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued ... cost no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 per ...

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short ... to discontinue production of certain insulin presentations and more dated delivery technologies ...